科伦药业
(002422)
| 流通市值：415.04亿 | | | 总市值：508.41亿 |
| 流通股本：12.99亿 | | | 总股本：15.91亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,259,244,936 | 18,512,918,907 | 13,276,729,763 | 9,083,327,620 |
| 营业收入 | 4,259,244,936 | 18,512,918,907 | 13,276,729,763 | 9,083,327,620 |
| 二、营业总成本 | 3,990,126,052 | 16,435,765,003 | 11,864,487,373 | 7,818,465,981 |
| 营业成本 | 2,329,222,978 | 9,655,237,375 | 6,918,962,787 | 4,563,768,076 |
| 税金及附加 | 70,650,188 | 257,850,170 | 187,048,638 | 121,486,067 |
| 销售费用 | 722,545,460 | 3,039,399,543 | 2,149,031,228 | 1,436,968,307 |
| 管理费用 | 269,857,187 | 1,206,565,999 | 930,472,675 | 616,388,260 |
| 研发费用 | 586,142,349 | 2,205,212,429 | 1,632,571,034 | 1,048,156,976 |
| 财务费用 | 11,707,890 | 71,499,487 | 46,401,011 | 31,698,295 |
| 其中:利息费用 | 23,116,294 | 102,836,710 | 83,743,427 | 53,757,701 |
| 其中:利息收入 | 13,480,148 | 81,421,100 | 50,582,017 | 22,871,210 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,195,352 | 27,611,838 | 21,419,033 | 15,139,177 |
| 加:投资收益 | 62,930,070 | 210,412,627 | 177,596,768 | 133,059,225 |
| 资产处置收益 | 1,154,694 | 5,320,176 | 5,742,400 | 6,486,961 |
| 资产减值损失(新) | 0 | -116,224,608 | -66,882,298 | -66,882,298 |
| 信用减值损失(新) | -13,733,534 | -23,501,166 | -36,107,467 | -28,311,025 |
| 其他收益 | 29,826,011 | 340,276,895 | 265,898,241 | 189,083,515 |
| 四、营业利润 | 356,491,477 | 2,521,049,666 | 1,779,909,067 | 1,513,437,194 |
| 加:营业外收入 | 101,292,643 | 80,913,387 | 4,640,487 | 2,471,001 |
| 减:营业外支出 | 16,735,911 | 198,127,465 | 135,619,472 | 98,258,746 |
| 五、利润总额 | 441,048,209 | 2,403,835,588 | 1,648,930,082 | 1,417,649,449 |
| 减:所得税费用 | -31,652,065 | 526,624,380 | 404,159,564 | 303,793,046 |
| 六、净利润 | 472,700,274 | 1,877,211,208 | 1,244,770,518 | 1,113,856,403 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 472,700,274 | 1,877,211,208 | 1,244,770,518 | 1,113,856,403 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 453,700,712 | 1,701,935,493 | 1,200,665,720 | 1,000,625,359 |
| 少数股东损益 | 18,999,562 | 175,275,715 | 44,104,798 | 113,231,044 |
| 扣除非经常损益后的净利润 | 381,454,885 | 1,596,533,268 | 1,146,949,563 | 985,477,298 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.29 | 1.07 | 0.75 | 0.63 |
| (二)稀释每股收益 | 0.29 | 1.07 | 0.75 | 0.63 |
| 八、其他综合收益 | -57,105,201 | -51,730,405 | -43,268,342 | -39,588,443 |
| 归属于母公司股东的其他综合收益 | -56,715,392 | -49,434,285 | -38,592,854 | -38,629,367 |
| 九、综合收益总额 | 415,595,073 | 1,825,480,803 | 1,201,502,176 | 1,074,267,960 |
| 归属于母公司股东的综合收益总额 | 396,985,320 | 1,652,501,208 | 1,162,072,866 | 961,995,992 |
| 归属于少数股东的综合收益总额 | 18,609,753 | 172,979,595 | 39,429,310 | 112,271,968 |
| 公告日期 | 2026-04-29 | 2026-04-03 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |